The Latest Breaking News from HIMS

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the current price.

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Hims stock surged Friday after facing backlash over its provocative Super Bowl ad.

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025

The telemedicine industry is transforming healthcare with digital platforms, growing consumer demand, and innovative care delivery models. As the sector evolves, telemedicine stocks like Doximity (DOCS), Hims & Hers Health (HIMS), and GoodRx Holdings (GDRX) are well-positioned to capitalize on this trend. Read on….

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

This whale alert can help traders discover the next big trading opportunities.

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.